These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
802 related articles for article (PubMed ID: 25262426)
1. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426 [TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672 [TBL] [Abstract][Full Text] [Related]
3. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer. Ma YF; Yang B; Li J; Zhang T; Guo JT; Chen L; Li M; Chu J; Liang CY; Liu Y Genet Mol Res; 2015 Oct; 14(4):13998-4008. PubMed ID: 26535714 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571 [TBL] [Abstract][Full Text] [Related]
5. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775 [TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469 [TBL] [Abstract][Full Text] [Related]
7. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407 [TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer. Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232 [TBL] [Abstract][Full Text] [Related]
9. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460 [TBL] [Abstract][Full Text] [Related]
10. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732 [TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827 [TBL] [Abstract][Full Text] [Related]
15. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135 [TBL] [Abstract][Full Text] [Related]
17. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer]. Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy]. Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
20. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]